CJC-1295 vs Ipamorelin
The distinction that mattersDifferent mechanisms, routinely combined. CJC-1295 acts on the GHRH receptor; ipamorelin acts on the ghrelin receptor. Neither combination has been tested in a clinical trial.
| CJC-1295 Research Use Only | Ipamorelin Research Use Only | |
|---|---|---|
| Evidence rating |
2/5 Limited
Evidence rating 2 out of 5: Limited
|
2/5 Limited
Evidence rating 2 out of 5: Limited
|
| Regulatory status | Investigational; clinical development discontinued. Not approved. Widely sold grey-market. | Investigational; phase 2 trials in postoperative ileus were discontinued. Not approved. Common in compounded wellness protocols. |
| Category | Growth Hormone Axis | Growth Hormone Axis |
| Drug class | GHRH analog; the DAC version bears a maleimide linker that binds serum albumin | Selective ghrelin receptor (GHS-R1a) agonist — pentapeptide |
| Route | Subcutaneous (research) | Subcutaneous (research) |
| Half-life | Non-DAC ~30 minutes; with DAC roughly 6–8 days | ~2 hours |
| Studied in | Small phase 1 pharmacokinetic and safety studies in healthy adults; development halted. | Phase 2 trials for postoperative ileus (development stopped); animal studies on bone and GH secretion. |
| Who should avoid it |
|
|
| Legal status | Not approved for human use in the US, EU or UK. Sale for human consumption is unlawful. | Not FDA-approved. FDA placed several GH-secretagogue peptides under increased compounding scrutiny. |
Benefits — CJC-1295
- Sustained GH and IGF-1 elevation
Phase 1 data showed multi-day increases in GH and IGF-1 after a single DAC dose — the pharmacology works as designed.
- Reduced injection frequency
The DAC version requires weekly rather than daily dosing.
- Synergy with ghrelin agonists
Combining a GHRH analog with a GHRP produces a larger GH pulse than either alone — well established in pituitary physiology.
Benefits — Ipamorelin
- Selective GH release
Clean pharmacology: GH rises without the cortisol and prolactin spikes seen with hexarelin or GHRP-6.
- Minimal appetite stimulation
Unlike GHRP-6, it does not produce the intense hunger that makes those peptides impractical.
- Good short-term tolerability
Trial safety data in the ileus program were reassuring over short exposures.
- Synergy with GHRH analogs
The two mechanisms combine to produce a larger pulse than either alone.
Risks & cons — CJC-1295
- Continuous GH exposure is non-physiological
Natural GH is pulsatile. Chronic flat elevation is the pattern seen in acromegaly, and its long-term consequences with this drug are untested.
- Development discontinued
The sponsor stopped work; no phase 2 or 3 efficacy or safety data exist.
- Insulin resistance and glucose elevation
Expected with sustained GH/IGF-1 elevation.
- Fluid retention, paraesthesia, carpal tunnel
GH-excess symptoms reported by users.
- Theoretical cancer promotion
IGF-1 is mitogenic; chronic elevation in people with occult neoplasia is a genuine unknown.
Risks & cons — Ipamorelin
- No proven clinical benefit
The trials that were run targeted gut motility and were discontinued. Body-composition and recovery claims are untested.
- Unapproved and unregulated
Available only through compounding or grey-market suppliers, with corresponding quality uncertainty.
- Glucose and insulin effects
Raising the GH axis can worsen insulin sensitivity over time.
- Receptor desensitisation
Continuous ghrelin-receptor stimulation blunts the response; effects diminish with sustained use.
- Head/injection-site reactions
Headache, flushing and local reactions are reported.
A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.